February 21, 2012 — Theragenics Corp.,a medical device company serving the surgical products and prostate cancer treatment markets, announced that it has purchased Core Oncology’s prostate brachytherapy customer base. The asset acquisition was effective on Feb. 17, 2012. The total purchase price is structured as an “earn-out” equal to one times the actual revenue generated from the acquired customers over the twelve-month period beginning September 2012 and ending August 2013 in excess of a $2.5 million threshold amount. Theragenics paid $3.8 million in cash at closing as prepayment of a portion of the earn-out, and will make quarterly earn-out payments thereafter. The company expects to fund the quarterly earn-out payments from operating cash flow and existing cash balances.
“The Core transaction and additional iodine business demonstrates our continuing commitment to this treatment, the physicians and the patients who depend on it,” said M. Christine Jacobs, chairman and CEO of Theragenics Corporation. “The Core customers are in good hands.”
Travis Gay, CEO of Core Oncology, said, “Theragenics has been recognized as a leader and has been a valued partner of Core’s. I am confident that Theragenics will continue the outstanding quality and service to which the Core customers and patients they serve have grown accustomed.”
For more information: www.theragenics.com
July 24, 2024 
